Ann Lin

She joined a lab because the boss was also on a list.

The teenage logic was disarmingly direct. As a Stony Brook undergraduate - a double major in biochemistry and economics, a pairing that reads, in hindsight, like a map of her career - Lin learned that a young scientist named Jason Sheltzer had made the Forbes 30 Under 30 list in 2015. "I'm going to join this person's lab," she recalled deciding. "He's young and he's motivated and he seemed like he would be a great mentor. And he really is an amazing mentor!"

The internship at Cold Spring Harbor Laboratory turned into something bigger. Working in Sheltzer's group, Lin helped produce one of the more uncomfortable findings in cancer pharmacology: a drug that worked - but not for the reason everyone believed. The supposed target wasn't doing the killing. The drug fought cancer as a kind of happy accident, hitting something else entirely. The result forced a harder question onto the whole field: how do you prove a therapy works the way you think it does?

A few years later, her name was on the list too.

In December 2019, Forbes named Lin to its 30 Under 30 in Science. She was 23, a Stanford PhD candidate, and already an author on research that had embarrassed a drug target. The teenager who picked a mentor off a list had become the kind of scientist who ends up on one.

Between the bench and the boardroom there was a detour through Norway, where she went as a Fulbright Scholar and built something that sounds like science fiction and is merely Tuesday in modern biology: an organ-on-a-chip device wired into a mass spectrometer, so a drug's effect on living tissue could be measured in real time. Economics, genetics, instrumentation, markets - the resume keeps refusing to stay in one lane.

The unsexy bottleneck.

Plenty of founders chase the next molecule. Lin went after the part everyone hates and no one fixes: the search, the sourcing, the contracts, the project management. The middle of the sentence, not the headline.

It is a contrarian read on her own field. She co-founded a drug-discovery company, Meliora, and could have stayed in pure science. Instead she concluded the binding constraint on biotech speed was operational, not scientific - that a small company with a brilliant idea still loses months finding someone to run an assay. Cromatic's wager is that fixing logistics compounds across an entire industry.

Backed to build it.

The 2023 seed round paired specialist agri-bio funds AgFunder and LifeX with brand-name generalists - Accel, Kleiner Perkins, Lux Capital, FJ Labs. The company has also partnered with accelerators including Nucleate, SOSV, and ValleyDAO, plugging it into the early-stage biotech pipeline at the exact moment those founders first need outside labs.